Europe—Key Dates and Roadmap for Implementation of New Rules on Medical Devices

On November 13, 2017, the European Commission (EC) published its roadmap (Roadmap) for the implementation of Regulation (EU) 2017/745 on Medical Devices (MDR).

The MDR entered into force on May 26, 2017, but most of its provisions will only apply as of May 26, 2020, and several key aspects of the new European medical device system still require further implementation by the EC. Overall, it seems that the MDR will not become operational anytime soon despite the industry being encouraged to be compliant therewith as soon as possible.

This Legal Update highlights the key dates for the MDR and explains the Roadmap. It does not cover Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices although IVD devices are also covered by the Roadmap.

**Key Dates for the Medical Devices Regulation (MDR)**


**May 5, 2017:** Publication of the MDR in the Official Journal of the European Union.

**May 26, 2017:** Entry into force of the MDR.

**November 26, 2017:**
- Notified Bodies (NBs) may submit an application for designation under the MDR.
- Designation of the national authorities responsible for the implementation of the MDR and establishment of the Medical Device Coordination Group (MDCG)

**May 26, 2018:** Cooperation of the National Competent Authorities (NCA) for the uniform implementation of the MDR.

**February 25, 2020:** Adoption of national penalties for infringements of the MDR.

**March 25, 2020:** Operation of Eudamed, the European database of medical devices.

**May 26, 2020:** Application of the MDR.
- Medical devices that do not comply with the MDR may no longer be placed on the market.
- Reporting of serious adverse events and device deficiencies in accordance with the MDR for all clinical investigations, including those started before the application of the MDR.
- Adoption of common specifications for single-use devices and their reprocessing.
- NBs that are not designated and notified in accordance with the MDR may no longer carry out conformity assessment procedures and issue certificates.
May 26, 2021: Unique Device Identification (UDI) carriers must be placed on implantable devices and class III devices.

May 27, 2022: Certificates of conformity issued by NBs in accordance with Annex 4 to the AIMDD or Annex IV to the MDD before May 25, 2017, become void.

May 26, 2023: UDI carriers must be placed on class IIa and class IIb devices.

May 27, 2024: Certificates of conformity issued by NBs in accordance with the AIMDD or the MDD from May 25, 2017, become void.

May 26, 2025: UDI carriers must be placed on class I devices.

May 27, 2025: Devices lawfully placed on the market under the AIMDD and MDD may no longer be made available on the market or put into service.

May 27, 2027: Application of the coordinated assessment procedure for clinical investigations under the MDR.

Roadmap for Implementation

The Roadmap describes the next steps and actions to undertake for implementing the MDR.

Specific provisions of the MDR empower the EC to take implementing actions, but guidance documents have to be adopted beforehand in order to ensure a harmonized interpretation of the legislation. The Roadmap does not detail the content of the EC’s implementing measures and therefore does not inform the industry about the actions to be taken in order to comply with the MDR. Rather, it outlines how the different working parties may contribute to the development of those measures, i.e., may develop the documents and structures on which to build the implementation. The Roadmap is more a pre-roadmap than a roadmap as most of the actions described in it involve developing guidance documents, clarifications and best practices to implement the medical devices rules.

The Roadmap focuses on eight technical areas. For each area, it lists activities, including a brief description, their priority level and the parties responsible for carrying them out. Overall, the Roadmap envisages 35 activities in relation to medical devices (MDs), of which 17 are classified as “high priority.” It is remarkable that the package “market surveillance” has no “high priority” item.

<table>
<thead>
<tr>
<th>HIGH PRIORITY</th>
<th>MEDIUM OR LOW PRIORITY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical evaluation &amp; clinical investigation (MD)</strong></td>
<td>- Clinical evaluation work package</td>
</tr>
<tr>
<td></td>
<td>- Template document development</td>
</tr>
<tr>
<td></td>
<td>- Clinical investigation assessment</td>
</tr>
<tr>
<td></td>
<td>- Common specifications</td>
</tr>
<tr>
<td><strong>Scope &amp; classification</strong></td>
<td>- Information and guidance on classification for MDs (changes on classification rules)</td>
</tr>
<tr>
<td></td>
<td>- Implementing act on reprocessing SUDs for MDs</td>
</tr>
<tr>
<td></td>
<td>- Common specifications for annex XVI products (non-medical medical devices)</td>
</tr>
<tr>
<td><strong>HIGH PRIORITY</strong></td>
<td><strong>MEDIUM OR LOW PRIORITY</strong></td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------</td>
</tr>
</tbody>
</table>
| **NBs & conformity assessment** | – Implementing act(s) with list(s) of codes and corresponding types of devices to describe the scope of the designation  
– Guidance to be issued on designation process for joint assessments under the new regulations  
– Capacity and expertise of assessors – training based on a gap analysis  
– Conformity assessment – clarity over procedures for NBs | – Guidance on different routes for conformity assessment  
– DAs review of NB assessments (clinical and technical included) |
| **Post-market surveillance & vigilance** | – Guidance on requirements for vigilance reporting  
– Develop and agree on terminology for Adverse Nomenclature and patient harm | – Define trend, signal detection and signal management processes  
– Development of revised templates (MIR, FSN, FSCA, Trend, PSR, Vigilance exchange forms, and new forms for PSURs + summary of safety & performance and PMCF/PMPF alignment) |
| **Eudamed & UDI** | – Uniform input into the design/development of a functioning Eudamed  
– Guidelines for manufacturers on UDI assignments  
– Guidelines on UDI carriers, UDI marking | – Guidelines/clarification on registration and UDI in specific cases (Parallel trades, OBL, Reprocessors, etc.)  
– Guidelines for NCA on how to perform validation of registration data  
– Importer/distributor certificates and SUD conformity assessment |
| **Market surveillance** | | – Cooperation between NCAs  
– Production of general, high-level CAMD guidance/infographics for economic operators (EO) clarifying expectations  
– NCA market surveillance obligations in accordance with Article 93 (MDR)  
– Understanding of transitional arrangements between RAMS (Regulation on Accreditation and Market Surveillance - New Legislative Framework) and MDR, as well as “gap analysis” of major changes  
– Definition of Market Surveillance activities |
<table>
<thead>
<tr>
<th>HIGH PRIORITY</th>
<th>MEDIUM OR LOW PRIORITY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IVD-specific issues</strong></td>
<td>– Transitional problems &amp; uncertainties, and risks to continued supply of safe devices</td>
</tr>
<tr>
<td></td>
<td>– Resources requirements</td>
</tr>
<tr>
<td></td>
<td>– Defining Responsibilities</td>
</tr>
<tr>
<td></td>
<td>– Clarify MDCG role in the governance of the regulations</td>
</tr>
<tr>
<td></td>
<td>– Expert Panels and Expert laboratories</td>
</tr>
<tr>
<td><strong>Over-arching &amp; cross-cutting priorities</strong></td>
<td>– Stakeholder engagement (ongoing)</td>
</tr>
<tr>
<td></td>
<td>– Contributing to ensure Eudamed is fit for purpose for audit and from go-live (2020)</td>
</tr>
</tbody>
</table>

For more information section about the topics raised in this Legal Update, please contact any of the following lawyers.

**Geneviève Michaux**
Brussels
+32 2 502 5517
gmichaux@mayerbrown.com

**Christoph J. Crützen**
Düsseldorf
+49 211 86224 120
ccruetzen@mayerbrown.com

Mayer Brown is a global legal services organization advising clients across the Americas, Asia, Europe and the Middle East. Our presence in the world’s leading markets enables us to offer clients access to local market knowledge combined with global reach.

We are noted for our commitment to client service and our ability to assist clients with their most complex and demanding legal and business challenges worldwide. We serve many of the world’s largest companies, including a significant proportion of the Fortune 100, FTSE 100, CAC 40, DAX, Hang Seng and Nikkei index companies and more than half of the world’s largest banks. We provide legal services in areas such as banking and finance; corporate and securities; litigation and dispute resolution; antitrust and competition; US Supreme Court and appellate matters; employment and benefits; environmental; financial services regulatory and enforcement; government and global trade; intellectual property; real estate; tax; restructuring, bankruptcy and insolvency; and wealth management.

Please visit www.mayerbrown.com for comprehensive contact information for all Mayer Brown offices.

Any tax advice expressed above by Mayer Brown LLP was not intended or written to be used, and cannot be used, by any taxpayer to avoid U.S. federal tax penalties. If such advice was written or used to support the promotion or marketing of the matter addressed above, then each offeree should seek advice from an independent tax advisor.

Mayer Brown comprises legal practices that are separate entities (the “Mayer Brown Practices”). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe-Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown México, S.C., a sociedad civil formed under the laws of the State of Durango, Mexico; Mayer Brown JSM, a Hong Kong partnership and its associated legal practices in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. Mayer Brown Consulting (Singapore) Pte. Ltd and its subsidiary, which are affiliated with Mayer Brown, provide customs and trade advisory and consultancy services, not legal services.

“Mayer Brown” and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

This publication provides information and comments on legal issues and developments of interest to our clients and friends. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek legal advice before taking any action with respect to the matters discussed herein.

© 2017 The Mayer Brown Practices. All rights reserved.